BioSpace News Archive

Aptevo Therapeutics Inc. today reported its financial results for the year ended December 31, 2021 and provided 2021 business highlights.

EpiEndo Pharmaceuticals is pleased to announce the appointment of Stefan Petursson as Chief Financial Officer (CFO), starting 1 April 2022.

Biomind Labs Inc. is pleased to announce the commencement of a commercial clinical trial on its proprietary drug candidate BMND06, a novel formulation based on the psychedelic molecule mescaline.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, will announce fourth quarter and full year 2021 financial results and provide a business update on Tuesday, March 29, 2022.

The Pancreatic Cancer Action Network, a leading nonprofit in the fight against pancreatic cancer, has announced the latest updates to its innovative adaptive clinical trial, Precision PromiseSM, including the addition of an investigational treatment from global healthcare company, Novartis, as well as the opening of five additional sites across the country.

Dermata Therapeutics, Inc., a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced that the Company will be participating in the 2022 Maxim Group Virtual Growth Conference, taking place March 28-30, 2022.

Previously offered as a beta application on iOS, Rootines, a patient engagement platform is now available commercially.

COTA, Inc. , an oncology real-world data and analytics company, announced today that Miruna Sasu , Ph.D. MBA, has been appointed president and chief executive officer.

Entrepreneur and philanthropist Jennifer Rubio has been named to the Board of Directors at Scripps Research.

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that an investigator-initiated trial (IIT) will commence shortly in the US investigating 64Cu SAR-bisPSMA in prostate cancer (NCT05286840)[1}.